Format
Sort by

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 131

1.

Plasma selenium, manganese superoxide dismutase, and intermediate- or high-risk prostate cancer.

Chan JM, Oh WK, Xie W, Regan MM, Stampfer MJ, King IB, Abe M, Kantoff PW.

J Clin Oncol. 2009 Aug 1;27(22):3577-83. doi: 10.1200/JCO.2008.18.8938. Epub 2009 Jun 15.

2.

Single-nucleotide polymorphisms within the antioxidant defence system and associations with aggressive prostate cancer.

Abe M, Xie W, Regan MM, King IB, Stampfer MJ, Kantoff PW, Oh WK, Chan JM.

BJU Int. 2011 Jan;107(1):126-34. doi: 10.1111/j.1464-410X.2010.09344.x.

3.

Interaction between single nucleotide polymorphisms in selenoprotein P and mitochondrial superoxide dismutase determines prostate cancer risk.

Cooper ML, Adami HO, Grönberg H, Wiklund F, Green FR, Rayman MP.

Cancer Res. 2008 Dec 15;68(24):10171-7. doi: 10.1158/0008-5472.CAN-08-1827.

4.

Manganese superoxide dismutase polymorphism, prediagnostic antioxidant status, and risk of clinical significant prostate cancer.

Li H, Kantoff PW, Giovannucci E, Leitzmann MF, Gaziano JM, Stampfer MJ, Ma J.

Cancer Res. 2005 Mar 15;65(6):2498-504.

5.

Manganese superoxide dismutase (MnSOD) gene polymorphism, interactions with carotenoid levels and prostate cancer risk.

Mikhak B, Hunter DJ, Spiegelman D, Platz EA, Wu K, Erdman JW Jr, Giovannucci E.

Carcinogenesis. 2008 Dec;29(12):2335-40. doi: 10.1093/carcin/bgn212. Epub 2008 Sep 10.

6.

Impact of positive surgical margins on prostate-specific antigen failure after radical prostatectomy in adjuvant treatment-naïve patients.

Ploussard G, Agamy MA, Alenda O, Allory Y, Mouracade P, Vordos D, Hoznek A, Abbou CC, de la Taille A, Salomon L.

BJU Int. 2011 Jun;107(11):1748-54. doi: 10.1111/j.1464-410X.2010.09728.x. Epub 2010 Sep 30.

7.

Association of genetic variations of selenoprotein genes, plasma selenium levels, and prostate cancer aggressiveness at diagnosis.

Xie W, Yang M, Chan J, Sun T, Mucci LA, Penney KL, Lee GS, Kantoff PW.

Prostate. 2016 May;76(7):691-9. doi: 10.1002/pros.23160. Epub 2016 Feb 5.

PMID:
26847995
9.

High Gleason scores and lower prostate-specific antigen levels in a single institution over the past decade.

Abouelfadel Z, Miller GJ, Glode LM, Akduman B, Donohue RE, Nedrow A, Crawford ED.

Clin Prostate Cancer. 2002 Sep;1(2):115-7.

PMID:
15046702
10.

Role of prostate specific antigen and immediate confirmatory biopsy in predicting progression during active surveillance for low risk prostate cancer.

Adamy A, Yee DS, Matsushita K, Maschino A, Cronin A, Vickers A, Guillonneau B, Scardino PT, Eastham JA.

J Urol. 2011 Feb;185(2):477-82. doi: 10.1016/j.juro.2010.09.095. Epub 2010 Dec 17.

11.

Prostate cancers diagnosed at repeat biopsy are smaller and less likely to be high grade.

Tan N, Lane BR, Li J, Moussa AS, Soriano M, Jones JS.

J Urol. 2008 Oct;180(4):1325-9; discussion 1329. doi: 10.1016/j.juro.2008.06.022. Epub 2008 Aug 15.

PMID:
18707706
12.

Factors predicting prostatic biopsy Gleason sum under grading.

Stackhouse DA, Sun L, Schroeck FR, Jayachandran J, Caire AA, Acholo CO, Robertson CN, Albala DM, Polascik TJ, Donatucci CF, Maloney KE, Moul JW.

J Urol. 2009 Jul;182(1):118-22; discussion 123-4. doi: 10.1016/j.juro.2009.02.127. Epub 2009 May 17.

PMID:
19447436
13.

Single nucleotide polymorphisms and the likelihood of prostate cancer at a given prostate specific antigen level.

Loeb S, Carter HB, Walsh PC, Isaacs WB, Kettermann A, Tanaka T, Ferrucci L, Metter EJ.

J Urol. 2009 Jul;182(1):101-4; discussion 105. doi: 10.1016/j.juro.2009.02.126. Epub 2009 May 17.

14.

Predictive value of the differential expression of the urokinase plasminogen activation axis in radical prostatectomy patients.

Gupta A, Lotan Y, Ashfaq R, Roehrborn CG, Raj GV, Aragaki CC, Montorsi F, Shariat SF.

Eur Urol. 2009 May;55(5):1124-33. doi: 10.1016/j.eururo.2008.06.054. Epub 2008 Jun 23.

PMID:
18585843
15.

Antioxidant and vitamin E transport genes and risk of high-grade prostate cancer and prostate cancer recurrence.

Bauer SR, Richman EL, Sosa E, Weinberg V, Song X, Witte JS, Carroll PR, Chan JM.

Prostate. 2013 Dec;73(16):1786-95. doi: 10.1002/pros.22717. Epub 2013 Aug 29.

PMID:
24038157
16.

A prospective study of plasma selenium levels and prostate cancer risk.

Li H, Stampfer MJ, Giovannucci EL, Morris JS, Willett WC, Gaziano JM, Ma J.

J Natl Cancer Inst. 2004 May 5;96(9):696-703.

17.

Pretreatment prostate-specific antigen (PSA) velocity and doubling time are associated with outcome but neither improves prediction of outcome beyond pretreatment PSA alone in patients treated with radical prostatectomy.

O'Brien MF, Cronin AM, Fearn PA, Smith B, Stasi J, Guillonneau B, Scardino PT, Eastham JA, Vickers AJ, Lilja H.

J Clin Oncol. 2009 Aug 1;27(22):3591-7. doi: 10.1200/JCO.2008.19.9794. Epub 2009 Jun 8.

18.

Serum insulin level, disease stage, prostate specific antigen (PSA) and Gleason score in prostate cancer.

Lehrer S, Diamond EJ, Stagger S, Stone NN, Stock RG.

Br J Cancer. 2002 Sep 23;87(7):726-8.

19.

Intrinsic markers of tumour hypoxia and angiogenesis in localised prostate cancer and outcome of radical treatment: a retrospective analysis of two randomised radiotherapy trials and one surgical cohort study.

Vergis R, Corbishley CM, Norman AR, Bartlett J, Jhavar S, Borre M, Heeboll S, Horwich A, Huddart R, Khoo V, Eeles R, Cooper C, Sydes M, Dearnaley D, Parker C.

Lancet Oncol. 2008 Apr;9(4):342-51. doi: 10.1016/S1470-2045(08)70076-7. Epub 2008 Mar 17.

20.

Predicting prostate cancer risk through incorporation of prostate cancer gene 3.

Ankerst DP, Groskopf J, Day JR, Blase A, Rittenhouse H, Pollock BH, Tangen C, Parekh D, Leach RJ, Thompson I.

J Urol. 2008 Oct;180(4):1303-8; discussion 1308. doi: 10.1016/j.juro.2008.06.038. Epub 2008 Aug 15. Erratum in: J Urol. 2009 Mar;181(3):1507.

PMID:
18707724
Items per page

Supplemental Content

Write to the Help Desk